Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox–Gastaut syndrome

References

• ArzimanoglouAResnickTAll children who experience epileptic falls do not necessarily have Lennox-Gastaut syndrome…but many doEpileptic Disord201113suppl 1S3S1321669558
   PubMedGoogle Scholar
• ArzimanoglouAFrenchJBlumeWTLennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management and trial methodologyLancet Neurol20098829319081517
   PubMed Web of Science ®Google Scholar
• IoannidisJPHaidichABPappaMComparison of evidence of treatment effects in randomized and non-randomized studiesJAMA200128682183011497536
   PubMed Web of Science ®Google Scholar
• BourgeoisBFDouglassLMSankarRLennox-Gastaut syndrome: a consensus approach to differential diagnosisEpilepsia201455suppl 44925284032
   PubMed Web of Science ®Google Scholar
• GiarratanoMStandleyKBenbadisSRClobazam for treatment of epilepsyExpert Opin Pharmacother201213222723322242724
   PubMed Web of Science ®Google Scholar
• NeihSESherrEHEpileptic encephalopathies: new genes and pathwaysNeurotherapeutics20141179680625266964
   PubMed Web of Science ®Google Scholar
• ConryJANgYTPaolicchiJMClobazam in the treatment of Lennox-Gastaut syndromeEpilepsia20095051158116619170737
   PubMed Web of Science ®Google Scholar
• BeaumanoirABlumeWThe Lennox-Gastaut syndromeRogerJBureauMDravetCHGentonPTossinariCAWolfPEpileptic Syndromes in Infancy, Childhood and Adolescence3rdLondonJohn Libbey & Co Ltd.2002113135
   Google Scholar
• CrumrinePKLennox-Gastaut syndromeJ Child Neurol200217suppl 1S70S7511918467
   PubMed Web of Science ®Google Scholar
• MarkandONLennox-Gastaut syndrome (childhood epileptic encephalopathy)J Clin Neurophysiol20032042644114734932
   PubMed Web of Science ®Google Scholar
• AutryARTrevathanEVan Naarden BraunKYeargin-AllsoppMIncreased risk of death among children with Lennox-Gastaut syndrome and infantile spasmJ Child Neurol20102544144720023065
   PubMed Web of Science ®Google Scholar
• LeahyJTChu-ShoreCJFisherJLClobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndromeNeurophsychiatr Dis Treat20117673681
   PubMed Web of Science ®Google Scholar
• WhelessJWClarkeDFArzimanoglouACarpenterDTreatment of pediatric epilepsy: European expert opinion, 2007Epileptic Disord2007935341218077226
   PubMed Web of Science ®Google Scholar
• SchmidtDBourgeoisBA risk-benefit assessment of therapies for Lennox-Gastaut syndromeDrug Saf20002246747710877040
   PubMed Web of Science ®Google Scholar
• FrenchJSmithMFaughtEThe use of felbamate in the treatment of patients with intractable epilepsy-report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy SocietyEpilepsia199940803808
   Web of Science ®Google Scholar
• World Health Organization regulatory mattersWHO Drug Info19948152160
   Google Scholar
• GubermanAHBesagFMBrodieMJLamotrigine-associated rash: risk/benefit considerations in adults and childrenEpilepsia19994098599110403224
   PubMed Web of Science ®Google Scholar
• GlauserTABehavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patientsJ Child Neurol200419suppl 1S25S3815526968
   PubMedGoogle Scholar
• SankarRGABAA receptor physiology and its relationship to the mechanism of action of the 1,5 benzodiazepine clobazamCNS Drugs201226322924422145708
   PubMed Web of Science ®Google Scholar
• WhelessJWPhelpsSJClobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromesJ Child Neurol201328221922923112237
   PubMed Web of Science ®Google Scholar
• RobertsonMMCurrent status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazamEpilepsia198627suppl 1S27S413527689
   PubMedGoogle Scholar
• WieckHHBlahaLHeerklotzBA clinical view of clobazamBr J Clin Pharmacol19797suppl 110981128
   Google Scholar
• ChapmanAGHortonRWMeldrumBSAnticonvulsant action of a 1,5-benzodiazepine, clobazam, in reflex epilepsyEpilepsia197919329329998317
   PubMed Web of Science ®Google Scholar
• JensenAAHammerHEbertBClobazam and its active metabolite, N-desmethylclobazam, are partial benzodiazepine receptor agonists at cloned GABAA receptors expressed in Xenopus laevis oocytesNeurology201078Meeting Abstracts 1P05.085
   Google Scholar
• McKernanRMRosahlTWReynoldsDSSedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtypeNat Neurosci2000358759210816315
   PubMed Web of Science ®Google Scholar
• DoiTUedaYTokumaruJWillmoreLJMolecular regulation of glutamate and GABA transporter proteins by clobazam during eliptogenesis in FE(+++)-induced epileptic ratsBrain Res Mol Brain Res2005142919616274841
   PubMedGoogle Scholar
• NgYTCollinsSDClobazamNeurotherapeutics2007413814417199029
   PubMed Web of Science ®Google Scholar
• NgYTConryJADrummondRStolleJWeinbergMAOV-1012 Study InvestigatorsRandomized, phase III study results of clobazam in Lennox-Gastaut syndromeNeurology2011771473148121956725
   PubMed Web of Science ®Google Scholar
• NgYTConryJPaolicchiJOV-1004 Study InvestigatorsLong-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension studyEpilepsy Behav20122568769423141144
   PubMed Web of Science ®Google Scholar
• ConryJANgYTKernitskyLOV-1004 Study InvestigatorsStable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 yearsEpilepsia201455455856724580023
   PubMed Web of Science ®Google Scholar
• CramerJASapinCFranҁoisCIndirect comparison of clobazam and other therapies for Lennox-Gastaut syndromeActa Neurol Scand2013128919923410109
   PubMed Web of Science ®Google Scholar
• WhelessJWIsojarviJLeeDDrummondRBenbadisSRClobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experienceEpilepsy Bahav2014414752
   PubMed Web of Science ®Google Scholar
• GastautHLowMDAntiepileptic properties of clobazam, a 1–5 benzodiazepine, in manEpilepsia197920437446383476
   PubMed Web of Science ®Google Scholar
• RuppWBadianMChristOPharmacokinetics of single and multiple doses of clobazam in humansBr J Clin Pharmacol19797suppl 151S57S35205
   PubMedGoogle Scholar
• WalzerMBekerskyIBlumRATolbertDPharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymesPharmacotherapy201232434035322422635
   PubMed Web of Science ®Google Scholar
• FisherJLInteractions between modulators of the BABAA receptor: stiripentol and benzodiazepinesEur J Pharmacol201165416016521237147
   PubMed Web of Science ®Google Scholar
• BunHMonjanel-MouterdeSNoelFDurandACanoJPEffects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazamPharmacol Toxicol19906721361402255665
   PubMedGoogle Scholar
• SeoTNagataRIshitsuTImpact of CYP2C19 polymorphisms on the efficacy of clobazam therapyPharmacogenomics2008952753718466100
   PubMed Web of Science ®Google Scholar
• ONFI^® (clobazam) [package insert]Deerfield, ILLundbeck2014
   Google Scholar
• BardyAHSeppäläTSalokorpiTGranströmMLSantavuoriPMonitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsyBrain Dev1991131741791928610
   PubMed Web of Science ®Google Scholar
• TolbertDHarrisSIBekerskyILeeDIsojarviJWithdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndromeEpilepsy Behav201437111524949576
   PubMed Web of Science ®Google Scholar
• DenisCFatséasMLavieEAuriacombeMPharmacological interventions for benzodiazepine mono-dependence management in outpatient settingsCochrane Database Syst Rev20063CD00519416856084
   PubMedGoogle Scholar
• PeturssonHLaderMHWithdrawal from long-term benzodiazepine treatmentBr Med J (Clin Res Ed)1981283643645
   PubMed Web of Science ®Google Scholar
• PeturssonHJLaderMHWithdrawal reaction from clobazamBr Med J (Clin Res Ed)198128219311932
   PubMedGoogle Scholar
• RudolphUCrestaniFBenkeDBenzodiazepine actions mediated by specific gamma-aminobutyric acid (A) receptor subtypesNature199940179680010548105
   PubMed Web of Science ®Google Scholar
• BorlandRGNicholsonANImmediate effects on human performance of a 1,5-benzodiazepine (clobazam) compared with the 1,4-benzodiazepines, chlordiazepoxide bydrochloride and diazepamBr J Clin Pharmacol1975232152211234503
   PubMed Web of Science ®Google Scholar
• BiehlBStudies of clobazam and car-drivingBr J Clin Pharmacol19797suppl 185S90S35213
   PubMedGoogle Scholar
• SaletuBGrunbergerJBernerPOn differences between 1,5 and 1,4-benzodiazepines: pharmaco-EEG and psychometric studies with clobazam and lorazepamHindmarkerIStonierPDTrimbleMRClobazam: Human Psychopharmacology and Clinical Applications. International Congress and Symposium Series 74LondonRoyal Society of Medicine19852346
   Google Scholar
• ClementsKMSkornickiMO’ullivanAKCost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndromeEpilepsy Behav20132918418923973644
   PubMed Web of Science ®Google Scholar
• BenedictAVerdianIMaclaineGThe cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UKPharmacoeconomics20102818519920151724
   PubMed Web of Science ®Google Scholar
• SkornickiMClementsKMO’SullivanAKBudget impact analysis of antiepileptic drugs for Lennox-Gastaut syndromeJ Manag Care Spec Pharm201420440040624684645
   PubMed Web of Science ®Google Scholar
• CamfieldPRDefinition and natural history of Lennox-Gastaut syndromeEpilepsia201152suppl 5S3S9
   PubMed Web of Science ®Google Scholar
• KobauRZahranHThurmanDJCenters for Disease Control and Prevention (CDC)Epilepsy surveillance among adults – 9 states. Behavioral Risk Factor Surveillance System, 2005MMWR Surveill Summ200857612018685554
   PubMedGoogle Scholar